The differential involvement of adrenoceptors in challenges of different intensities.
Haller
J
J
Institute of Experimental Medicine, Budapest, Hungary.
Pintér
I
I
Gyertyán
I
I
Békási
E
E
Makara
G B
GB
D058668:Adrenergic alpha-1 Receptor Antagonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001599:Berberine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004597:Electroshock; D005106:Exploratory Behavior / Q000187:drug effects*; D019329:Idazoxan / Q000494:pharmacology*; D008297:Male; D011224:Prazosin / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D018340:Receptors, Adrenergic, alpha-1 / Q000502:physiology*; D018341:Receptors, Adrenergic, alpha-2 / Q000502:physiology*
D058668:Adrenergic alpha-1 Receptor Antagonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D018340:Receptors, Adrenergic, alpha-1; D018341:Receptors, Adrenergic, alpha-2; D001599:Berberine; C048886:7,8-(methylenedioxy)-14-hydroxyberbane; D011433:Propranolol; D011224:Prazosin; D019329:Idazoxan